AR121695A1 - Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos - Google Patents

Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos

Info

Publication number
AR121695A1
AR121695A1 ARP210100792A ARP210100792A AR121695A1 AR 121695 A1 AR121695 A1 AR 121695A1 AR P210100792 A ARP210100792 A AR P210100792A AR P210100792 A ARP210100792 A AR P210100792A AR 121695 A1 AR121695 A1 AR 121695A1
Authority
AR
Argentina
Prior art keywords
binding
antigen
dll3
multispecific antigen
binding molecules
Prior art date
Application number
ARP210100792A
Other languages
English (en)
Spanish (es)
Inventor
Sotaro Naoi
Shu Feng
Tomoyuki Igawa
Shu Wen Samantha Ho
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR121695A1 publication Critical patent/AR121695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP210100792A 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos AR121695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020062326 2020-03-31

Publications (1)

Publication Number Publication Date
AR121695A1 true AR121695A1 (es) 2022-06-29

Family

ID=77855554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100792A AR121695A1 (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos

Country Status (18)

Country Link
US (3) US11274151B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126969A4 (cg-RX-API-DMAC7.html)
JP (3) JP7085666B2 (cg-RX-API-DMAC7.html)
KR (2) KR102505383B1 (cg-RX-API-DMAC7.html)
CN (1) CN115397866B (cg-RX-API-DMAC7.html)
AR (1) AR121695A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173587A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002624A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015305A2 (cg-RX-API-DMAC7.html)
CR (2) CR20250287A (cg-RX-API-DMAC7.html)
IL (1) IL296803A (cg-RX-API-DMAC7.html)
MX (1) MX2022012091A (cg-RX-API-DMAC7.html)
PE (1) PE20230077A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022500013A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105302PA (cg-RX-API-DMAC7.html)
TW (3) TWI799824B (cg-RX-API-DMAC7.html)
WO (1) WO2021200898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
JP7736688B2 (ja) * 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
JP7557922B2 (ja) 2021-09-29 2024-09-30 中外製薬株式会社 Dll3標的多重特異性抗原結合分子の使用
EP4482586A1 (en) 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
KR20250027562A (ko) * 2022-06-23 2025-02-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Dll3 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
WO2024111657A1 (ja) 2022-11-25 2024-05-30 中外製薬株式会社 タンパク質の製造方法
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
CN121620371A (zh) 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0328966Y2 (cg-RX-API-DMAC7.html) 1987-10-16 1991-06-20
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター3
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−3
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
AU2757500A (en) 1999-02-10 2000-08-29 Human Genome Sciences, Inc. 33 human secreted proteins
WO2001012664A2 (en) 1999-08-19 2001-02-22 Chiron Corporation Notch receptor ligands and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
ATE346866T1 (de) 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
JP4906094B2 (ja) 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN101123983A (zh) 2004-10-27 2008-02-13 米迪缪尼股份有限公司 特定修饰对相关抗原的亲和力来调节抗体的特异性
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
CA2596248A1 (en) 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
EP1973945A4 (en) 2006-01-16 2009-11-18 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ, エルエルシー インフルエンザウイルスに対する中和抗体
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗hb−egf抗体を有効成分として含む医薬組成物
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US8580927B2 (en) 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
AR073538A1 (es) 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
BR112016020065A2 (pt) 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
JPWO2015146438A1 (ja) 2014-03-26 2017-04-13 国立大学法人東北大学 ヒト上皮増殖因子受容体を標的とした二重特異性抗体
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3305322A4 (en) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
JP6675017B2 (ja) 2016-05-02 2020-04-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft コントースボディ−単鎖標的結合物質
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標的化4-1bb(cd137)アゴニストとの併用療法
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
JP7803856B2 (ja) 2020-02-05 2026-01-21 中外製薬株式会社 組換え抗原結合分子を製造するおよび/または濃縮するための方法
JP7736688B2 (ja) 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof

Also Published As

Publication number Publication date
TW202204409A (zh) 2022-02-01
CA3173587A1 (en) 2021-10-07
TWI909146B (zh) 2025-12-21
JP2026031947A (ja) 2026-02-25
CO2022015305A2 (es) 2022-11-08
TW202612736A (zh) 2026-04-01
US20210301016A1 (en) 2021-09-30
US20220251201A1 (en) 2022-08-11
KR102505383B1 (ko) 2023-03-02
BR112022019498A2 (pt) 2022-11-16
JP2022122972A (ja) 2022-08-23
CN115397866B (zh) 2025-10-31
US11718672B2 (en) 2023-08-08
EP4126969A1 (en) 2023-02-08
MX2022012091A (es) 2022-10-13
JP7085666B2 (ja) 2022-06-16
TWI799824B (zh) 2023-04-21
CL2022002624A1 (es) 2023-06-02
AU2021250186A1 (en) 2022-12-01
PE20230077A1 (es) 2023-01-11
TW202325741A (zh) 2023-07-01
CN115397866A (zh) 2022-11-25
US20240010725A1 (en) 2024-01-11
CR20250287A (es) 2025-08-28
US11274151B2 (en) 2022-03-15
SG11202105302PA (en) 2021-11-29
KR20230035138A (ko) 2023-03-10
PH12022500013A1 (en) 2023-09-11
WO2021200898A1 (en) 2021-10-07
JP2021159081A (ja) 2021-10-11
KR20220100520A (ko) 2022-07-15
CR20220541A (es) 2022-11-28
IL296803A (en) 2022-11-01
EP4126969A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
CO2022015305A2 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
CL2023002099A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
AR114550A1 (es) Moléculas de unión al antígeno anti-cd137 y sus usos
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CR20230229A (es) Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
EA201070163A1 (ru) Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение
CR20190296A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
MX2022009936A (es) Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
BR112022013678A2 (pt) Quelatos macrocíclicos e seus usos
BR112018072716A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme.
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
CO2022001083A2 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
CL2023001509A1 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
CL2025002072A1 (es) Inhibidores de prmt5–mta.
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos